Sarcoma Foundation of America Applauds FDA Approval of Yondelis

-Drug Approved for Use in Treatment of Advanced Liposarcoma and Leiomyosarcoma- DAMASCUS, Md. – October 23, 2015 – The Sarcoma Foundation of America (SFA) applauds the announcement by the Food and Drug Administration (FDA) that the drug Yondelis (trabectedin, marketed by Janssen) has been approved by the agency for the treatment… Read More